Skip to main content

FDA-Cleared Vivace® Remains Available

Posted April 24, 2020

Dear Valued Aesthetics Biomedical Client,

First and foremost, we want to express our concern for the impact that COVID-19 is having on all your businesses and lives, along with wishes that your family and friends remain safe and healthy.  It is these priorities that must be foremost in our mind daily as we all attempt to navigate the unexpected.  We also want to thank you for your ongoing business and your help in making Vivace™ the premium brand amongst RF Microneedling devices.  Our goal is to make sure you have facts and accurate information regarding the Vivace™, supporting its position as an award-winning quality product, with great value and a strong ROI for your practice.  We want to clear up any misinformation that has recently been advanced by one of our competitors.

As you know, Vivace™ is a robust and multifunctional device and we remain committed to improving outcomes through education and novel treatment approaches. With Aesthetics Biomedical’s (ABM) development and advancement of the 3D Precision approach, utilizing the more robust 1MHz frequency has become the setting of choice.  The preferred use of the 1MHz is based on scientific and clinical data generated by Aesthetics Biomedical and well-documented patient outcomes.  We believe that the 1MHz is the gold standard in treatment based on its ability to create the thermal injury necessary to achieve the outcomes desired by both patients and practitioners. Vivace™, using 1MHz, is recognized by practitioners as delivering their patients’ desired results, providing relatively pain-free treatments, resulting in essentially no downtime and delivering strong financial returns based on patient satisfaction and return visits – features of the Vivace™ that our competition still cannot compete with. Attached is the latest treatment protocol for 3D Precision microneedling at the 1MHz.

The Vivace™ is an FDA-cleared Class II medical device for use at the higher 1MHz frequency level.  It was cleared in January 2016 to treat fine lines and facial wrinkles and remains the gold standard today.

ABM will always operate with full transparency, quality products and implementing daily our corporate core values of honesty, integrity, creativity, quality and responsiveness.


MaryAnn Guerra

President & Chief Executive Officer

Aesthetics Biomedical

Stay Connected